Motion Serifos: a Study to Investigate the Efficacy of Tradipitant in Participants Affected by Motion Sickness
- Registration Number
- NCT05903924
- Lead Sponsor
- Vanda Pharmaceuticals
- Brief Summary
A multi-center, randomized, double-blind, placebo-controlled study to investigate the efficacy of tradipitant in participants affected by motion sickness during travel
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 316
Inclusion Criteria
- History of motion sickness
- Age 18-75
Read More
Exclusion Criteria
- Nausea-inducing disorder other than motion sickness
- BMI>40
- History of intolerance and/or hypersensitivity to Neurokinin-1 Receptor antagonists
Read More
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Tradipitant High Dose Tradipitant - Placebo Placebo - Tradipitant Low Dose Tradipitant -
- Primary Outcome Measures
Name Time Method Prevention of vomiting measured by Vomiting Assessment (VA) 1 day Prevention of vomiting measured by Vomiting Assessment (VA) score. The VA is a 1-item questionnaire to objectively measure the incidence of emesis. Participants will indicate whether or not they have vomited.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (5)
Pacific Research Partners
🇺🇸San Diego, California, United States
Lumos Clinical Research
🇺🇸San Jose, California, United States
Santa Monica Clinical Trials
🇺🇸Santa Monica, California, United States
Beacon Clinical Research
🇺🇸Boston, Massachusetts, United States
Manhattan Medical Research
🇺🇸New York, New York, United States